HRP20220742T1 - Sredstva koja se vežu na psma i njihova upotreba - Google Patents
Sredstva koja se vežu na psma i njihova upotreba Download PDFInfo
- Publication number
- HRP20220742T1 HRP20220742T1 HRP20220742TT HRP20220742T HRP20220742T1 HR P20220742 T1 HRP20220742 T1 HR P20220742T1 HR P20220742T T HRP20220742T T HR P20220742TT HR P20220742 T HRP20220742 T HR P20220742T HR P20220742 T1 HRP20220742 T1 HR P20220742T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- image
- radioisotope
- formula
- group
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 33
- 238000000034 method Methods 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- -1 p-methoxybenzyl Chemical group 0.000 claims 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229910052789 astatine Inorganic materials 0.000 claims 2
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 238000012800 visualization Methods 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 101100097467 Arabidopsis thaliana SYD gene Proteins 0.000 claims 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8546208P | 2008-08-01 | 2008-08-01 | |
| US11179108P | 2008-11-06 | 2008-11-06 | |
| EP17167057.3A EP3222615B1 (en) | 2008-08-01 | 2009-07-31 | Psma-binding agents and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220742T1 true HRP20220742T1 (hr) | 2022-10-28 |
Family
ID=41610978
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220742TT HRP20220742T1 (hr) | 2008-08-01 | 2009-07-31 | Sredstva koja se vežu na psma i njihova upotreba |
| HRP20171133TT HRP20171133T1 (hr) | 2008-08-01 | 2009-07-31 | Psma-vezujući agensi i njihove uporabe |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171133TT HRP20171133T1 (hr) | 2008-08-01 | 2009-07-31 | Psma-vezujući agensi i njihove uporabe |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US8778305B2 (https=) |
| EP (3) | EP3222615B1 (https=) |
| JP (6) | JP5588441B2 (https=) |
| KR (1) | KR101664855B1 (https=) |
| CN (3) | CN107382846B (https=) |
| AU (1) | AU2009276423B2 (https=) |
| CA (2) | CA2732632C (https=) |
| CY (3) | CY1119367T1 (https=) |
| DK (2) | DK3222615T3 (https=) |
| ES (2) | ES2914593T3 (https=) |
| FI (1) | FIC20230033I1 (https=) |
| FR (1) | FR23C1044I2 (https=) |
| HK (1) | HK1247197A1 (https=) |
| HR (2) | HRP20220742T1 (https=) |
| HU (3) | HUE059436T2 (https=) |
| LT (3) | LT2318366T (https=) |
| LU (1) | LUC00323I2 (https=) |
| NL (1) | NL301250I2 (https=) |
| NO (1) | NO2024006I1 (https=) |
| PL (2) | PL3222615T3 (https=) |
| PT (2) | PT2318366T (https=) |
| RU (1) | RU2494096C2 (https=) |
| SI (2) | SI2318366T1 (https=) |
| SM (1) | SMT201700371T1 (https=) |
| WO (1) | WO2010014933A2 (https=) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
| US9422234B2 (en) * | 2007-11-30 | 2016-08-23 | The Johns Hopkins University | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer |
| WO2009084995A1 (en) | 2007-12-28 | 2009-07-09 | Exini Diagnostics Ab | System for detecting bone cancer metastases |
| PT2318366T (pt) * | 2008-08-01 | 2017-08-02 | Univ Johns Hopkins | Agentes de ligação a psma e suas utilizações |
| EP2433322A4 (en) | 2009-05-19 | 2015-11-04 | East Penn Mfg Co | COMPOSITE CURRENT COLLECTOR AND RELATED METHODS |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| WO2013028664A1 (en) | 2011-08-22 | 2013-02-28 | Siemens Medical Solutions Usa, Inc. | Psma imaging agents |
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| ES2729555T3 (es) * | 2011-11-30 | 2019-11-04 | Univ Johns Hopkins | Inhibidores homomultivalentes y heteromultivalentes de antígeno de membrana específico de próstata (PMSA) y usos de los mismos |
| US20140065070A1 (en) * | 2012-08-28 | 2014-03-06 | Mcmaster University | Methods of preparing triazole-containing radioiodinated compounds |
| EA201590783A1 (ru) * | 2012-11-15 | 2015-11-30 | Эндосайт, Инк. | Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma |
| PL2970345T3 (pl) * | 2013-03-15 | 2019-12-31 | Cancer Targeted Technology Llc | Znakowane 18F środki do obrazowania PET ukierunkowane na PSMA |
| US10232058B2 (en) | 2013-10-14 | 2019-03-19 | The Johns Hopkins University | Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy |
| EP3456700A1 (en) | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| JP6292568B2 (ja) * | 2013-11-06 | 2018-03-14 | 国立大学法人京都大学 | ウレア誘導体化合物、これを含有する放射性医薬 |
| EP3533473A3 (en) | 2013-11-14 | 2019-12-18 | Endocyte, Inc. | Compounds for positron emission tomography |
| US9713649B2 (en) | 2014-01-24 | 2017-07-25 | The Cleveland Clinic Foundation | PSMA-targeting imaging agents |
| US10556916B2 (en) * | 2014-04-01 | 2020-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography |
| EP2993171A1 (en) * | 2014-09-04 | 2016-03-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the production of 18F-labeled PSMA-specific PET-tracers |
| EP3183236B1 (en) | 2014-08-24 | 2022-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
| EP3209336B1 (en) * | 2014-10-20 | 2019-12-11 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP3011976A1 (en) * | 2014-10-20 | 2016-04-27 | Deutsches Krebsforschungszentrum | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents |
| WO2016065142A2 (en) | 2014-10-22 | 2016-04-28 | The Johns Hopkins University | New scaffolds and multifunctional intermediates for imaging psma and cancer therapy |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| WO2016112382A2 (en) * | 2015-01-09 | 2016-07-14 | The Johns Hopkins University | Intranasal administration of glutamate carboxypeptidase (gcp-ii) inhibitors |
| US10869940B2 (en) | 2015-06-12 | 2020-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted photoacoustic compounds, formulations, and uses thereof |
| EP3337520A1 (en) * | 2015-08-20 | 2018-06-27 | Universität zu Köln | Pain tracking by pet-imaging (pain-trap) |
| KR102233726B1 (ko) | 2015-09-30 | 2021-03-31 | 도이체스 크렙스포르슝스첸트룸 | 전립선 특이적 막 항원（psma)의 18f-태그된 저해제 및 전립선암에 대한 조영제로서 이의 용도 |
| US20200231614A1 (en) * | 2015-10-22 | 2020-07-23 | The Johns Hopkins University | Psma targeted radiohalogenated ureas for cancer radiotherapy |
| KR101639599B1 (ko) | 2015-11-09 | 2016-07-14 | 서울대학교산학협력단 | 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물 |
| EP3400229B1 (en) | 2016-01-10 | 2024-03-06 | Provincial Health Services Authority | 18/19f-labelled compounds which target the prostate specific membrane antigen |
| DK3481804T3 (da) * | 2016-06-10 | 2025-01-13 | Univ Johns Hopkins | Forbedret syntese af radioaktivt mærket hæmmer af prostataspecifikt membranantigen (PSMA) [18F]DCFPyL |
| CN109843339B (zh) * | 2016-06-23 | 2023-07-07 | 康奈尔大学 | 影响肿瘤杀伤的双重靶向构建体 |
| US10806806B2 (en) | 2016-06-23 | 2020-10-20 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
| AU2017348111B2 (en) | 2016-10-27 | 2023-04-06 | Progenics Pharmaceuticals, Inc. | Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications |
| JP6999960B2 (ja) * | 2016-11-17 | 2022-01-19 | 思路迪（北京）医薬科技有限公司 | 抗がん作用を有する化合物およびその製造方法ならびにその使用 |
| DE102016122273B4 (de) * | 2016-11-18 | 2018-06-21 | Abx Advanced Biochemical Compounds Gmbh | Präkursoren für die Radiofluorierung |
| EP3609541A4 (en) | 2017-04-05 | 2021-04-07 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
| MX2019012017A (es) | 2017-04-07 | 2020-02-12 | Juno Therapeutics Inc | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. |
| WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| WO2018236115A1 (ko) | 2017-06-19 | 2018-12-27 | (주)퓨쳐켐 | 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도 |
| DK3643707T3 (da) | 2017-06-19 | 2022-05-09 | Futurechem Co Ltd | 18f-mærket forbindelse til diagnosticering af prostatkræft, og anvendelse deraf |
| EA202090776A1 (ru) | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
| BR112020011727A2 (pt) * | 2017-12-11 | 2020-11-17 | Technische Universität München | ligantes de psma para imageamento e endorradioterapia |
| US10973486B2 (en) | 2018-01-08 | 2021-04-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
| US12602772B2 (en) | 2018-01-08 | 2026-04-14 | Progenics Pharmaceuticals, Inc. | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
| ES3026214T3 (en) | 2018-01-08 | 2025-06-10 | Progenics Pharm Inc | System and method for rapid neural network-based image segmentation |
| US11813340B2 (en) | 2018-02-06 | 2023-11-14 | The Johns Hopkins University | PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| CN112368024A (zh) | 2018-04-17 | 2021-02-12 | 恩多塞特公司 | 治疗癌症的方法 |
| CN109160899B (zh) * | 2018-05-16 | 2021-06-04 | 上海如絮生物科技有限公司 | 一种亲水性吡啶类化合物、中间体、其制备方法及应用 |
| CN109160896B (zh) * | 2018-05-16 | 2021-06-25 | 上海如絮生物科技有限公司 | 一种亲水性吡啶类化合物中间体及其制备方法 |
| CN109160898B (zh) * | 2018-05-16 | 2021-06-04 | 上海如絮生物科技有限公司 | 一种亲水性吡啶类化合物中间体及其制备方法 |
| US20210338846A1 (en) * | 2018-07-30 | 2021-11-04 | The Johns Hopkins University | Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy |
| WO2020077259A1 (en) | 2018-10-11 | 2020-04-16 | Progenics Pharmaceuticals, Inc | Combination therapy for treating metastatic prostate cancer |
| RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
| WO2020139012A1 (ko) | 2018-12-27 | 2020-07-02 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
| EP4597424A3 (en) | 2019-01-07 | 2025-10-29 | Exini Diagnostics AB | Systems and methods for platform agnostic whole body image segmentation |
| PL239934B1 (pl) | 2019-04-12 | 2022-01-31 | Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom | Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty |
| AU2020257786B2 (en) | 2019-04-17 | 2025-10-23 | Provincial Health Services Authority | Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer |
| JP7539921B2 (ja) | 2019-04-24 | 2024-08-26 | プロジェニクス ファーマシューティカルズ， インコーポレイテッド | 核医学画像における強度ウィンドウ処理の双方向調節のためのシステムおよび方法 |
| BR112021021011A2 (pt) | 2019-04-24 | 2021-12-14 | Exini Diagnostics Ab | Sistemas e métodos para análise automatizada e interativa de imagens de varredura óssea para detecção de metástases |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| BR112021025810A2 (pt) | 2019-06-21 | 2022-05-10 | Provincial Health Services Authority | Compostos radiomarcados direcionando o antígeno de membrana específico da próstata |
| RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
| AU2020336190A1 (en) * | 2019-08-30 | 2022-03-24 | Memorial Sloan Kettering Cancer Center | Novel theranostic agents for PSMA positive cancers |
| US12417533B2 (en) | 2019-09-27 | 2025-09-16 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| US11564621B2 (en) | 2019-09-27 | 2023-01-31 | Progenies Pharmacenticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| US11900597B2 (en) | 2019-09-27 | 2024-02-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| US11544407B1 (en) | 2019-09-27 | 2023-01-03 | Progenics Pharmaceuticals, Inc. | Systems and methods for secure cloud-based medical image upload and processing |
| KR102269315B1 (ko) | 2019-10-24 | 2021-06-24 | 서울대학교산학협력단 | 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물 |
| US11321844B2 (en) | 2020-04-23 | 2022-05-03 | Exini Diagnostics Ab | Systems and methods for deep-learning-based segmentation of composite images |
| US11386988B2 (en) | 2020-04-23 | 2022-07-12 | Exini Diagnostics Ab | Systems and methods for deep-learning-based segmentation of composite images |
| CN111548305B (zh) * | 2020-05-12 | 2021-08-31 | 北京师范大学 | 一种可用于靶向psma的喹啉类化合物及其制备方法 |
| US11721428B2 (en) | 2020-07-06 | 2023-08-08 | Exini Diagnostics Ab | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
| CA3163190A1 (en) | 2020-07-06 | 2022-01-13 | Exini Diagnostics Ab | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
| EP4244216A1 (en) | 2020-11-12 | 2023-09-20 | ABX Advanced Biochemical Compounds GmbH | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| CN114685599A (zh) * | 2020-12-30 | 2022-07-01 | 南京江原安迪科正电子研究发展有限公司 | 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途 |
| KR20240072996A (ko) | 2021-07-30 | 2024-05-24 | 오사카 유니버시티 | 방사성 표지된 화합물 및 이의 용도 |
| CA3231578A1 (en) | 2021-10-08 | 2023-04-13 | Exini Diagnostics Ab | Systems and methods for automated identification and classification of lesions in local lymph and distant metastases |
| US20250332265A1 (en) | 2021-11-09 | 2025-10-30 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
| CA3256961A1 (en) | 2022-06-08 | 2023-12-14 | Progenics Pharmaceuticals, Inc. | SYSTEMS AND METHODS FOR ASSESSING THE BURDEN AND PROGRESSION OF A DISEASE |
| KR20250130683A (ko) | 2023-01-10 | 2025-09-02 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 리간드-약물 접합체 |
| US20240285248A1 (en) | 2023-02-13 | 2024-08-29 | Progenics Pharmaceuticals, Inc. | Systems and methods for predicting biochemical progression free survival in prostate cancer patients |
| CN116217505B (zh) * | 2023-03-17 | 2024-10-01 | 南京医科大学 | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 |
| US20240354940A1 (en) | 2023-04-07 | 2024-10-24 | Progenics Pharmaceuticals, Inc. | Systems and methods for facilitating lesion inspection and analysis |
| WO2025072177A1 (en) | 2023-09-25 | 2025-04-03 | Progenics Pharmaceuticals, Inc. | Systems and methods for automated cancer staging and risk prediction |
| WO2025090594A1 (en) * | 2023-10-25 | 2025-05-01 | The Johns Hopkins University | Deep transfer learning for fully automated tumor quantification and prognosis of cancer on pet/ct |
| DE102023133281B8 (de) * | 2023-11-28 | 2025-07-24 | Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien Gmbh | Radiotracer und Präkursoren für diese Radiotracer sowie Verwendung dieser Radiotracer als Diagnostika und Therapeutika |
| CN117670883B (zh) * | 2024-01-31 | 2024-05-07 | 中国医学科学院北京协和医院 | 一种鉴别高低级别膀胱癌的方法、设备和系统 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2233269C2 (ru) * | 1998-11-02 | 2004-07-27 | Авентис Фарма Лимитед | Замещенные анилиды, фармацевтическая композиция и способ лечения |
| JP3750494B2 (ja) | 1999-08-31 | 2006-03-01 | 松下電器産業株式会社 | 半導体装置 |
| WO2006093991A1 (en) * | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
| EP2097111B1 (en) | 2006-11-08 | 2015-07-15 | Molecular Insight Pharmaceuticals, Inc. | Heterodimers of glutamic acid |
| ES2700234T3 (es) * | 2007-06-26 | 2019-02-14 | Univ Johns Hopkins | Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes |
| EP2436376B1 (en) * | 2007-09-28 | 2014-07-09 | BIND Therapeutics, Inc. | Cancer cell targeting using nanoparticles |
| PT2318366T (pt) * | 2008-08-01 | 2017-08-02 | Univ Johns Hopkins | Agentes de ligação a psma e suas utilizações |
| GB0905438D0 (en) | 2009-03-30 | 2009-05-13 | Ge Healthcare Ltd | Radiolabelling reagents and methods |
| DK3481804T3 (da) * | 2016-06-10 | 2025-01-13 | Univ Johns Hopkins | Forbedret syntese af radioaktivt mærket hæmmer af prostataspecifikt membranantigen (PSMA) [18F]DCFPyL |
-
2009
- 2009-07-31 PT PT98036700T patent/PT2318366T/pt unknown
- 2009-07-31 EP EP17167057.3A patent/EP3222615B1/en active Active
- 2009-07-31 ES ES17167057T patent/ES2914593T3/es active Active
- 2009-07-31 HU HUE17167057A patent/HUE059436T2/hu unknown
- 2009-07-31 AU AU2009276423A patent/AU2009276423B2/en active Active
- 2009-07-31 CA CA2732632A patent/CA2732632C/en active Active
- 2009-07-31 LT LTEP09803670.0T patent/LT2318366T/lt unknown
- 2009-07-31 LT LTEP17167057.3T patent/LT3222615T/lt unknown
- 2009-07-31 DK DK17167057.3T patent/DK3222615T3/da active
- 2009-07-31 HR HRP20220742TT patent/HRP20220742T1/hr unknown
- 2009-07-31 CA CA2987744A patent/CA2987744C/en active Active
- 2009-07-31 CN CN201710536671.3A patent/CN107382846B/zh active Active
- 2009-07-31 WO PCT/US2009/052456 patent/WO2010014933A2/en not_active Ceased
- 2009-07-31 HU HUE09803670A patent/HUE034027T2/en unknown
- 2009-07-31 CN CN202110689899.2A patent/CN113563262A/zh active Pending
- 2009-07-31 EP EP09803670.0A patent/EP2318366B1/en active Active
- 2009-07-31 US US13/057,044 patent/US8778305B2/en active Active
- 2009-07-31 ES ES09803670.0T patent/ES2634894T3/es active Active
- 2009-07-31 EP EP22163541.0A patent/EP4089074A1/en active Pending
- 2009-07-31 PL PL17167057.3T patent/PL3222615T3/pl unknown
- 2009-07-31 SM SM20170371T patent/SMT201700371T1/it unknown
- 2009-07-31 DK DK09803670.0T patent/DK2318366T3/en active
- 2009-07-31 SI SI200931704T patent/SI2318366T1/sl unknown
- 2009-07-31 RU RU2011107752/04A patent/RU2494096C2/ru active
- 2009-07-31 KR KR1020117004960A patent/KR101664855B1/ko active Active
- 2009-07-31 JP JP2011521362A patent/JP5588441B2/ja active Active
- 2009-07-31 CN CN200980139135.3A patent/CN102171187B/zh active Active
- 2009-07-31 PL PL09803670T patent/PL2318366T3/pl unknown
- 2009-07-31 HR HRP20171133TT patent/HRP20171133T1/hr unknown
- 2009-07-31 SI SI200932167T patent/SI3222615T1/sl unknown
- 2009-07-31 PT PT171670573T patent/PT3222615T/pt unknown
-
2012
- 2012-02-27 HK HK18106684.8A patent/HK1247197A1/zh unknown
-
2014
- 2014-03-14 US US14/211,683 patent/US9226981B2/en active Active
- 2014-07-25 JP JP2014152130A patent/JP5806765B2/ja active Active
-
2015
- 2015-09-04 JP JP2015174731A patent/JP6030724B2/ja active Active
-
2016
- 2016-01-04 US US14/987,032 patent/US9861713B2/en active Active
- 2016-10-20 JP JP2016206120A patent/JP6524046B2/ja active Active
-
2017
- 2017-07-31 CY CY20171100825T patent/CY1119367T1/el unknown
-
2018
- 2018-01-08 US US15/864,236 patent/US10500292B2/en active Active
- 2018-11-26 JP JP2018220353A patent/JP7277113B2/ja active Active
-
2019
- 2019-11-05 US US16/674,089 patent/US20200282083A1/en not_active Abandoned
-
2021
- 2021-01-28 JP JP2021012046A patent/JP7219497B2/ja active Active
- 2021-04-22 US US17/237,850 patent/US12070513B2/en active Active
-
2022
- 2022-06-09 CY CY20221100403T patent/CY1125468T1/el unknown
-
2023
- 2023-11-02 FI FIC20230033C patent/FIC20230033I1/fi unknown
- 2023-11-03 CY CY2023024C patent/CY2023024I2/el unknown
- 2023-11-06 FR FR23C1044C patent/FR23C1044I2/fr active Active
- 2023-11-14 HU HUS2300039C patent/HUS2300039I1/hu unknown
- 2023-11-14 LT LTPA2023534C patent/LTC2318366I2/lt unknown
- 2023-11-15 NL NL301250C patent/NL301250I2/nl unknown
- 2023-12-01 LU LU00323C patent/LUC00323I2/fr unknown
-
2024
- 2024-02-01 NO NO2024006C patent/NO2024006I1/no unknown
- 2024-07-15 US US18/772,628 patent/US20250177578A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220742T1 (hr) | Sredstva koja se vežu na psma i njihova upotreba | |
| ES2636618T3 (es) | Compuestos peptídicos a base de urea útiles para la detección entre otros de cáncer de próstata | |
| US20230147035A1 (en) | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer | |
| ES2943458T3 (es) | Radiofármacos, agentes de radioimagen y usos de los mismos | |
| ES2743482T3 (es) | Inhibidores de PSMA marcados con metal/radiometal para obtención de imágenes dirigidas a PSMA y radioterapia | |
| US10280183B2 (en) | Therapeutic agent for treating tumors | |
| JP2011529919A5 (https=) | ||
| ES2675320T3 (es) | Dendrímeros dirigidos a PSMA | |
| ES2924289T3 (es) | Ligandos amínicos tipo jaula para metalorradiofármacos | |
| Joyard et al. | Synthesis of new 18F-radiolabeled silicon-based nitroimidazole compounds | |
| AU2017203512A1 (en) | 18F-saccharide-folates | |
| ES2763950T3 (es) | Agente de contraste y radiofarmacéutico multimodal para formación de imágenes y una terapia dirigida guiada por imágenes | |
| ES2616793T3 (es) | Derivados de quinoxalina marcados como productos radiofarmacéuticos multimodales y sus precursores | |
| CN111548305A (zh) | 一种可用于靶向psma的喹啉类化合物及其制备方法 | |
| US8329879B2 (en) | H3LMN compound used as radioactive agent for treatment of liver cancer and manufacturing method thereof | |
| JP2024534562A (ja) | １８ｆ標識フッ化シリル化合物の調製方法 | |
| HK40105413A (zh) | 制备18f标记的甲硅烷基氟化化合物的方法 | |
| JP2022538179A (ja) | 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 | |
| Mei et al. | Synthesis, radiolabeling and in vivo biological evaluation of 99m Tc-labeled MAG 3-based bisnitroimidazole complexes as tumor hypoxia markers. | |
| CA2382057A1 (en) | Macrocyclic chelants for metallopharmaceuticals |